Abstract:The complete eradication of human immunodeficiency virus type 1 (HIV-1) is blocked by latent reservoirs in CD4 + T cells and myeloid lineage cells. Toll-like receptors (TLRs) can induce the reversal of HIV-1 latency and trigger the innate immune response. To the best of our knowledge, there is little evidence show the "killing" effect of TLR1/2 agonists but only with a small "shock" potential. To identify a new approach for eradicating the HIV latent reservoir, we evaluated the effectiveness of SMU-Z1, a novel TLR1/2 small molecule agonist, in the "shock and kill" strategy. The results showed that SMU-Z1 can not only enhance latent HIV-1 transcription in ex vivo peripheral blood mononuclear cells (PBMCs) from aviremic HIV-1-infected donors receiving combined antiretroviral therapy (cART) but also in cells of myeloid-monocytic origin in vitro targeting the nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. Interestingly, activation marker CD69 was significantly upregulated in NK cells, B cells, and monocytes 48 hours after SMU-Z1 treatment. Furthermore, SMU-Z1 was able to activate T cells without global T cell activation, as well as increase NK cell degranulation and interferon-gamma (IFN-γ) production which further block HIV-1-infected CD4 lymphocytes. In summary, the present study found that SMU-Z1 can both enhance HIV-1 transcription and promote NK cell-mediated inhibition of HIV-1-infected autologous CD4 + T cells. These findings indicate that novel TLR1/2 agonist SMU-Z1 is a promising latency-reversing agent (LRA) for eradication of HIV-1 reservoirs. IMPORTANCE Multiple in vivo studies have shown that many LRAs implemented in the "shock and kill" approach could activate viral transcription but could not induce "killing" effectively. Therefore, a dual function LRA is needed for elimination of HIV-1 reservoirs. We previously developed a small molecule TLR1/2 agonist, SMU-Z1, and demonstrated that it could upregulate NK cells and CD8 + T cells with immune adjuvant and anti-tumor properties in vivo . In the present study, SMU-Z1 can activate innate immune cells without global T cell activation, induce production of proinflammatory and antiviral cytokines, and enhance the cytotoxic function of NK cells. We showed that SMU-Z1 displayed dual potential ex vivo in the "shock" of exposure of HIV-1 latently infected cells and in the "kill" of clearance of infected cells, which is critical for effective use in combination with therapeutic vaccines or broadly neutralizing antibody treatments aimed at curing AIDS.

Crispr/Grna-Directed Synergistic Activation Mediator (sam) Induces Specific, Persistent and Robust Reactivation of the Hiv-1 Latent Reservoirs

Inactivation of Latent HIV-1 Proviral DNA Using Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Treatment and the Assessment of Off-Target Effects.

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Dilazep Synergistically Reactivates Latent HIV-1 in Latently Infected Cells.

Specific reactivation of latent HIV-1 by dCas9-SunTag-VP64-mediated guide RNA targeting the HIV-1 promoter

Genome Scale Screening Identification of SaCas9/gRNAs for Targeting HIV-1 Provirus and Suppression of HIV-1 Infection

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

HIV-1 Proviral Genome Engineering with CRISPR-Cas9 for Mechanistic Studies

Gesicles packaging dCas9-VPR ribonucleoprotein complexes can combine with vorinostat and promote HIV proviral transcription.

TLR7 Agonist GS–9620 Combined with Nicotinamide Generate Viral Reactivation in Seronegative SHIVSF162P3-Infected Rhesus Monkeys

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Eliminates Ex Vivo Reservoirs

TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4+ T Cells

A CRISPR/Cas9 Screen Identifies the Histone Demethylase MINA53 As a Novel HIV-1 Latency-Promoting Gene (LPG).

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination

Delivering CRISPR to the HIV-1 reservoirs

Specific Reactivation of Latent HIV-1 with Designer Zinc-Finger Transcription Factors Targeting the HIV-1 5′-LTR Promoter

T cell stimulation remodels the latently HIV-1 infected cell population by differential activation of proviral chromatin

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies

The Bromodomain And Extraterminal Domain Inhibitor Bromosporine Synergistically Reactivates Latent Hiv-1 In Latently Infected Cells